Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Time to Recovery from Insulin-Induced Hypoglycemia: Dasiglucagon (Zegalogue) significantly reduced the time to recovery compared to placebo (mean difference [MD]: -24.73 minutes; 95% CI (Confidence interval): -30.94 to -18.52; p < 0.00001) and oral glucose (MD: -15.00 minutes; 95% CI: -20.33 to -9.67; p < 0.00001), but was comparable to conventional glucagon (MD: -0.76 minutes; 95% CI: -2.19 to 0.66; p = 0.29).
• Comparison to Other Ready-to-Use Glucagon Treatments: Zegalogue achieved high treatment success rates (>98%) similar to other glucagon treatments (Baqsimi and Gvoke), though Baqsimi had a faster time to treatment success and a lower mean maximum blood glucose (168 mg/dl) compared to Zegalogue (190 mg/dl).
• Subgroup Considerations: The effectiveness of dasiglucagon was observed across individuals with type 1 diabetes mellitus (T1DM) and was part of a broader comparison that included adults and children with type 1 and type 2 diabetes. No specific differences among subgroups were provided.
• In the comparison of ready-to-use glucagon treatments (Baqsimi, Gvoke, Zegalogue), there was a trend indicating fewer adults experiencing at least one treatment-emergent adverse event (TEAE) with Baqsimi compared to Gvoke or Zegalogue, but this difference was not statistically significant.
• No specific significant safety concerns or adverse effects were highlighted in the comparisons of dasiglucagon (Zegalogue) to placebo, oral glucose, or other glucagon treatments.
• The indirect treatment comparison included both adults and children with type 1 diabetes (T1D (T2D)) and type 2 diabetes (T2D), showing that dasiglucagon (Zegalogue) was effective for treating insulin-induced hypoglycemia. It demonstrated faster recovery times compared to placebo and oral glucose, with no significant differences when compared to conventional glucagon. Baqsimi was faster in achieving treatment success compared to Gvoke, with a lower maximum blood glucose value.